Aurinia (AUPH) news
Recent news
Aurinia: Teva can't launch generic voclosporin until Dec. 2036
Aurinia Pharmaceuticals has maintained legal protections for its flagship drug, LUPKYNIS (voclosporin), which is used to treat active lupus nephritis. As of August 2026, the U.S. Food and Drug Administration has not approved a generic version of the drug, and patent protections remain in place. The…
AInvest Wire · Aug 19, 2026Aurinia settles patent litigation with Teva
AInvest Wire · Aug 19, 2026Aurinia Pharmaceuticals 2Q operating income $46.3M, estimated $39M
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported operating income of $46.3 million , surpassing the estimated $39 million. This performance reflects continued growth in the company’s core operations, driven by strong net product sales of LUPKYNIS, its FDA-approved oral therapy for lupus…
AInvest Wire · Aug 6, 2026Aurinia Pharmaceuticals 2Q EPS 28c vs. 16c y/y
AInvest Wire · Aug 6, 2026Aurinia Pharmaceuticals 2Q total revenue $83.2M, est. $80.4M
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.